CIBC Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.41M | Sell |
10,609
-434
| -4% | -$77.3K | 0.01% | 638 |
|
|
2026
Q1 | $1.9M | Buy |
11,043
+50
| +0.5% | +$9.27K | ﹤0.01% | 643 |
|
|
2025
Q4 | $2.19M | Buy |
10,993
+4,526
| +70% | +$821K | 0.01% | 628 |
|
|
2025
Q3 | $1.01M | Sell |
6,467
-12
| -0.2% | -$1.91K | ﹤0.01% | 677 |
|
|
2025
Q2 | $983K | Sell |
6,479
-648
| -9% | -$86.4K | ﹤0.01% | 670 |
|
|
2025
Q1 | $1.07M | Sell |
7,127
-175
| -2% | -$29.3K | ﹤0.01% | 670 |
|
|
2024
Q4 | $1.35M | Sell |
7,302
-229
| -3% | -$44.1K | ﹤0.01% | 640 |
|
|
2024
Q3 | $1.48M | Buy |
7,531
+595
| +9% | +$124K | ﹤0.01% | 627 |
|
|
2024
Q2 | $1.43M | Sell |
6,936
-299
| -4% | -$67.8K | 0.01% | 618 |
|
|
2024
Q1 | $1.96M | Buy |
7,235
+217
| +3% | +$51.8K | 0.01% | 579 |
|
|
2023
Q4 | $1.66M | Sell |
7,018
-207
| -3% | -$40.7K | 0.01% | 589 |
|
|
2023
Q3 | $1.42M | Sell |
7,225
-66
| -0.9% | -$13.6K | 0.01% | 597 |
|
|
2023
Q2 | $1.53M | Sell |
7,291
-68
| -0.9% | -$13.5K | 0.01% | 601 |
|
|
2023
Q1 | $1.49M | Buy |
7,359
+232
| +3% | +$52.6K | 0.01% | 611 |
|
|
2022
Q4 | $1.55M | Buy |
7,127
+412
| +6% | +$90K | 0.01% | 600 |
|
|
2022
Q3 | $1.32M | Buy |
6,715
+616
| +10% | +$133K | 0.01% | 628 |
|
|
2022
Q2 | $1.3M | Buy |
6,099
+1,316
| +28% | +$322K | 0.01% | 614 |
|
|
2022
Q1 | $1.36M | Buy |
4,783
+47
| +1% | +$14.5K | ﹤0.01% | 635 |
|
|
2021
Q4 | $1.78M | Buy |
4,736
+302
| +7% | +$117K | 0.01% | 575 |
|
|
2021
Q3 | $1.83M | Buy |
4,434
+155
| +4% | +$64.4K | 0.01% | 546 |
|
|
2021
Q2 | $1.58M | Buy |
4,279
+2,447
| +134% | +$817K | 0.01% | 573 |
|
|
2021
Q1 | $531K | Sell |
1,832
-101
| -5% | -$28.1K | ﹤0.01% | 782 |
|
|
2020
Q4 | $483K | Hold |
1,933
| – | – | ﹤0.01% | 755 |
|
|
2020
Q3 | $438K | Buy |
1,933
+48
| +3% | +$9.96K | ﹤0.01% | 730 |
|
|
2020
Q2 | $329K | Hold |
1,885
| – | – | ﹤0.01% | 773 |
|
|
2020
Q1 | $238K | Hold |
1,885
| – | – | ﹤0.01% | 808 |
|
|
2019
Q4 | $288K | Buy |
1,885
+205
| +12% | +$28.4K | ﹤0.01% | 893 |
|
|
2019
Q3 | $222K | Hold |
1,680
| – | – | ﹤0.01% | 978 |
|
|
2019
Q2 | $238K | Hold |
1,680
| – | – | ﹤0.01% | 961 |
|
|
2019
Q1 | $244K | Buy |
+1,680
| New | +$221K | ﹤0.01% | 931 |
|
|
2018
Q4 | – | Sell |
-1,680
| Closed | -$226K | – | 1066 |
|
|
2018
Q3 | $226K | Buy |
+1,680
| New | +$207K | ﹤0.01% | 993 |
|
Other funds holding CRL
AI
CIBC Asset Management's CRL Position: Q2 2026 in Review
CIBC Asset Management reduced its Charles River Laboratories (CRL) stake by 3.9% in Q2 2026, selling an estimated $77.3K and leaving 10,609 shares worth $2.41M. The position accounts for 0.01% of the portfolio, ranked #638.
CIBC Asset Management first reported a position in CRL in Q3 2018 and has held it in 31 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- CIBC Asset Management held 10,609 shares of Charles River Laboratories worth $2.41M as of Q2 2026.
- CIBC Asset Management sold 434 Charles River Laboratories shares in Q2 2026, an estimated $77.3K.
- Charles River Laboratories made up 0.01% of CIBC Asset Management's portfolio in Q2 2026, its #638 holding.
- CIBC Asset Management first reported a position in Charles River Laboratories in Q3 2018 and has held it in 31 quarters since.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.